News & Events

Cellular Dynamics Partnering Forum at the
University of Wisconsin – Madison

Thursday, Jan 19, 2017

University of Wisconsin
Health Sciences Learning Center
750 Highland Ave. Room 1306
Madison, WI 53705

bioforward logoJoin Cellular Dynamics International, in cooperation with BioForward Wisconsin and the University of Wisconsin – Madison Office of Corporate Relations at the UW Health Sciences Learning Center for the Partnering Forum. ocr-logo_4c_lLearn more about research programs using the iPSC technology in a broad range of areas including regenerative medicine, disease modeling and research, and drug and therapeutics development. Researchers from the University of Wisconsin and The Medical College of Wisconsin will discuss how iPSC technology, along with CDI’s human tissue cell types are helping to accelerate their research.

Following the morning talks Cellular Dynamics is available for one-on-one meetings with individuals and companies interested in exploring potential partnering opportunities.

Forum Agenda

Wednesday, Jan 18

Evening - details to be providedCollaboration, Startup and Investor Social with Dinner
by Invitation

Thursday, Jan 19

8:00 - 11:30 amBreakfast Forum
8:00 am Networking
8:30 amIntroduction
Richard Moss, PhD
Professor, School of Medicine and Public Health,
University of Wisconsin
8:45 amCDI: Your Partner in Driving Research Forward
Bruce Novich, PhD
Chief Business Officer
Cellular Dynamics International
9:15 amAdvancing understanding and discovery of treatments for neurodevelopmental disorders
using human iPSCs


Anita Bhattacharyya, PhD
Senior Scientist, Waisman Center
University of Wisconsin

Human induced pluripotent stem cells (iPSCs) enable unique access to early development of the human brain. Thus, they are particularly valuable for the study of neurodevelopmental disorders whose defects arise during this critical period. The talk will highlight the utility of disorder-specific iPSCs as an experimentally accessible tool to study the molecular underpinnings of deficits that may enable discovery of the underlying causes of, and treatments for these disorders.
9:45 amUsing Patient Specific iPSC-derived Cardiomyocytes for Disease Modeling and Drug Screening

Andrea Matter, MS
Research Associate
Medical College of Wisconsin

Advances in human-induced pluripotent stem cell (hiPSC) technologies have helped overcome the limitations of animal models by providing a platform to study genotype-phenotype relationships in vitro. Human iPSC-derived cardiomyocytes (hiPSC-CMs) exhibit properties highly similar to their primary counterparts. Furthermore, they represent the genome of the selected individual, thus providing a relevant ‘patient in a dish’ model. In this presentation, we will discuss experiments focusing on improving our understanding of left ventricular hypertrophy (LVH) a common, independent risk factor for cardiovascular disease including myocardial infarction, stroke and heart failure. Current treatment focuses on prevention and regression by targeting risk factors such as hypertension or diabetes. We have used a hiPSC-CM based disease model of cardiac hypertrophy to study the impact of inter-individual genetic variability on phenotype, as well as to screen for potential new treatment options for this complex heart condition.
10:15 - 10:30 amCoffee Break
10:30 amProduction of Photoreceptor Precursors from Human Pluripotent Stem Cells

Joe Phillips, PhD
Postdoctoral Research Associate - Ophthalmology
Waisman Center
University of Wisconsin

Retinal pigmented epithelium derived from human pluripotent stem cells (hPSCs) has already shown promise for disease modeling, drug testing, and transplantation, due in large part to their favorable culture characteristics. More recently, similar applications for hPSC-derived neural retinal (NR) cultures have been investigated. NR can be isolated and differentiated from hPSCs in the form of 3-dimensional optic vesicle-like structures (OVs; also referred to as retinal organoids), which not only produce all major NR cell classes, including photoreceptors (PRs), but do so in a conserved spatiotemporal manner with the capacity to generate laminated tissues. However, numerous complexities and potential shortcomings currently exist with 3D hiPSC technology that need to be taken into consideration before employing it for disease modeling and therapeutic development. In particular, it is worthwhile to determine the capacity for such protocols to generate developing PRs with features indicative of authentic PR subtypes. This talk will discuss hPSC-OV technology, focusing on production of PR precursors and their potential to lead to treatments for retinal degenerative diseases.
11:00 am Assembly of Stem Cell-derived Human Tissues for Screening Applications

William Murphy, PhD
Professor, Biomedical Engineering, Orthopedics & Rehabilitation
Co-director, Stem Cell & Regenerative Medicine Center
University of Wisconsin

The need for human, organotypic culture models coupled with the requirements of contemporary drug discovery and toxin screening (i.e. reproducibility, high throughput, transferability of data, clear mechanisms of action) frame an opportunity for a paradigm shift. The next generation of high throughput cell-based assay formats will require a broadly applicable set of tools for human tissue assembly and analysis. Toward that end, we have recently focused on: i) generating iPS-derived cells that properly represent the diverse phenotypic characteristics of developing or mature human somatic cells; ii) assembling organotypic cell culture systems that are robust and reproducible; iii) translating organotypic cell culture models to microscale systems for high throughput screening; and iv) combining genomic analyses with bioinformatics to gain insights into organotypic model assembly and the pathways influenced by drugs and toxins. This talk will emphasize recent studies in which we have explored biologically driven assembly of organotypic vascular and neural tissues. These tissues mimic critical aspects of human tissues, and can be used for predictive neurodevelopmental toxicity, and for identification of vascular disrupting compounds. We have also begun to use assembled human tissues to develop models of developmental disorders, degenerative diseases, and infectious disease effects.
12:00 - 1:00 pmTrainees Networking
Opportunity to meet with CDI team members to discuss careers in the industry
12:00 - 1:00 pmEarly Stage Lunch
For junior faculty and early stage start-ups interested in using iPSC-derived cells in their work.
(Invite only)
12:00 - 4:00 pmOne on One Partnering Meetings
Attention academic and biotech investigators: Meet with CDI to discuss opportunities (20 minutes each)


About Cellular Dynamics

Cellular Dynamics was founded ten years ago in Madison by University of Wisconsin faculty and based on iPSC technology developed by Jamie Thomson and licensed from WARF. Cellular Dynamics International (CDI), a FUJIFILM company, is a leading developer and supplier of human cells used in basic and translational research, drug discovery, toxicity testing, and regenerative medicine applications. Leveraging technology that can be used to create induced pluripotent stem cells (iPSCs) and differentiated tissue-specific cells from any individual, CDI is committed to advancing life science research and transforming the therapeutic development process in order to fundamentally improve human health. The company’s inventoried iCell® products and donor-specific MyCell® Products are available in the quantity, quality, purity, and reproducibility required for drug and cell therapy development. For more information please visit www.cellulardynamics.com.